Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
13 October 2021 - 8:01AM
Edgar (US Regulatory)
2021-06-3000016049242021-01-012021-06-300001604924country:DE2021-06-300001604924ifrs-full:OrdinarySharesMember2021-04-012021-04-300001604924ifrs-full:OrdinarySharesMember2021-06-300001604924fwp:ConsultantsMemberfwp:DeferredSharesMember2016-10-102016-10-100001604924ifrs-full:IssuedCapitalMember2021-01-012021-06-300001604924ifrs-full:IssuedCapitalMember2020-01-012020-06-300001604924fwp:IfrsGeneralAndAdministrativeExpenseMember2021-01-012021-06-300001604924fwp:IfrsResearchAndDevelopmentExpenseMember2020-01-012020-06-300001604924fwp:IfrsGeneralAndAdministrativeExpenseMember2020-01-012020-06-300001604924ifrs-full:RetainedEarningsMember2021-06-300001604924ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-06-300001604924ifrs-full:IssuedCapitalMember2021-06-300001604924ifrs-full:RetainedEarningsMember2020-12-310001604924ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-12-310001604924ifrs-full:IssuedCapitalMember2020-12-310001604924ifrs-full:RetainedEarningsMember2020-06-300001604924ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-06-300001604924ifrs-full:IssuedCapitalMember2020-06-300001604924ifrs-full:RetainedEarningsMember2019-12-310001604924ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2019-12-310001604924ifrs-full:IssuedCapitalMember2019-12-310001604924ifrs-full:RetainedEarningsMember2021-01-012021-06-300001604924ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-01-012021-06-300001604924ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-01-012020-06-3000016049242020-06-3000016049242019-12-310001604924ifrs-full:CountryOfDomicileMember2021-01-012021-06-300001604924country:DEsrt:ScenarioPreviouslyReportedMember2017-01-012017-12-310001604924ifrs-full:CountryOfDomicileMember2017-01-012017-12-310001604924country:DE2017-01-012017-12-310001604924srt:DirectorMember2020-10-102020-10-100001604924country:DE2021-01-012021-06-300001604924fwp:BiogenMemberfwp:ServiceAgreementMember2017-02-0100016049242021-04-300001604924fwp:BiogenMemberfwp:ServiceAgreementMember2017-02-012017-02-280001604924ifrs-full:RetainedEarningsMember2020-01-012020-06-3000016049242016-10-102016-10-1000016049242020-01-012020-06-3000016049242021-06-3000016049242020-12-31iso4217:USDfwp:subsidiaryxbrli:sharesxbrli:pureiso4217:EURiso4217:USDxbrli:sharesfwp:EquityInstruments
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
October 12, 2021
Commission File Number: 001-36686
Forward Pharma A/S
Østergade 24A, 1
1100 Copenhagen K, Denmark
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1).
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7).
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
|
|
|
|
|
Forward Pharma A/S
|
|
|
|
|
Date: October 12, 2021
|
By:
|
/s/ Claus Bo Svendsen
|
|
|
|
Name: Claus Bo Svendsen
|
|
|
|
Title: Chief Executive Officer
|
Forward Pharma AS (NASDAQ:FWP)
Historical Stock Chart
From May 2024 to Jun 2024
Forward Pharma AS (NASDAQ:FWP)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Forward Pharma AS (NASDAQ): 0 recent articles
More Forward Pharma A/s News Articles